Coagulation Factor III
Coagulation Factor III Molekülinformation
| Englischer Name | Tissue factor | Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 7 | Target-Alias | Coagulation Factor III (Thromboplastin， Tissue Factor)，Thromboplastin，Coagulation Factor III， Tissue Factor，TFA，F3，TF，CD142 Antigen，CD142，Coagulation Factor III，Tissue Factor |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Tissue factor |
| Target-Alias | Coagulation Factor III (Thromboplastin， Tissue Factor)，Thromboplastin，Coagulation Factor III， Tissue Factor，TFA，F3，TF，CD142 Antigen，CD142，Coagulation Factor III，Tissue Factor |
| Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 7 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
Coagulation Factor III Produktliste
- Attribut
Protein (7)
- Produktbibliothek
Online (7)
- Spezies
Human (4)Mouse (1)Cynomolgus (1)Canine (1)
- Etikett
His Tag (4)Fc Tag (1)His Tag & Avi Tag (1)Fc Tag & Avi Tag (1)
- Marker
Unconjugated (5)Biotin-labeled (2)
In den Warenkorb legen
Gesamtmenge7
- 1
Coagulation Factor III Molekülhintergrund
Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.
Coagulation Factor III Molekülalias
Coagulation Factor III,Tissue Factor,TF,F3,CD142
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Anpocogin | AB-201 | Phase 3 Clinical | Dendreon Uk Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| XNW-28012 | XNW-28012; XNW28012 | Phase 3 Clinical | Shanghai Cigna Biotech Pharmaceutical Co Ltd | Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| MRG-004A | MRG004A | Phase 3 Clinical | Shanghai Miracogen Inc | Pancreatic Neoplasms; Solid tumours | Details |
| XB-002 | XB-002; ICON-2 | Phase 1 Clinical | Iconic Therapeutics Inc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms | Details |
| XB-371 | XB-371; XB371 | Phase 1 Clinical | Catalent Inc, Exelixis Inc | Neoplasms; Solid tumours | Details |
| STRO-004 | STRO-004 | Phase 1 Clinical | Sutro Biopharma Inc | Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| AMT-754 | ADCE-T02; AMT-754 | Phase 1 Clinical | Multitude Therapeutics Inc | Solid tumours | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Tisotumab vedotin | TF-011-MMAE | Approved | Genmab A/S | HuMax-TF, TIVDAK | United States | Uterine Cervical Neoplasms | Seagen Inc | 2021-09-20 | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation